Terapêutica Sistémica no Melanoma Avançado Systemic Therapy in Advanced Melanoma

Seite S, Del Marmol V, Moyal D, Friedman AJ. Public primary and secondary skin cancer prevention,perceptions and knowledge: An international cross-sectional survey. J Eur Acad Dermatol Venereol. 2017;31:815–20. doi.org/10.1111/jdv.14104.

Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: Projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Investig Dermatol. 2016; 136:1161–71. doi.org/10.1016/j.jid.2016.01.035.

Mariotto AB, Yabroff KR, Shad Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011; 103:117–28. doi.org/10.1093/jnci/djq495.

Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy [Internet]. Brisbane: Codon Publications; 2017. [accessed 2018 May 21]. doi.org/10.15586/codon.cutaneousmelanoma.2017.

Pires EM, Moura C. Systemic therapies for advanced melanoma: the immune checkpoint inhibitors. Rev Soc Port Dermatol Venereol. 2018: 76: doi.org/10.29021/spdv.76.3.970.

Boada A, Carrera C, Segura S, Collgros H, Pasquali P, Bodet D, et al. Cutaneous toxicities of new treatments for melanoma. Clin Transl Oncol. 2018 (in press). doi. org/10.1007/s12094-018-1891-7.